Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,100
datasets available to search
ShareScore release 0.9.0
Dataset results
2,100 results for “nodes”
An 82-Year old woman with a palpable lymph node
GEO Series GSE16575. Homo sapiens. 2 samples. Type: Genome variation profiling by array.
miRNAs expression in breast cancer tumor tissues with or without axillary lymph nodes metastastsis
GEO Series GSE100453. Homo sapiens. 24 samples. Type: Non-coding RNA profiling by array.
Gene expression profile at the single cell level of endothelial cells from tumor-draining lymph nodes of the melanoma mouse models
GEO Series GSE246146. Mus musculus. 5 samples. Type: Expression profiling by high throughput sequencing.
Molecular profiling of the mature Organiser (Hensen's node) as a stem zone.
GEO Series GSE107928. Gallus gallus. 12 samples. Type: Expression profiling by high throughput sequencing.
β-catenin is a node at orchestrating distinct aspects of epithelial-mesenchymal transition (EMT) and malignant mammary tumor progression
GEO Series GSE148843. Mus musculus. 56 samples. Type: Expression profiling by high throughput sequencing.
Single-cell RNA-sequencing of CD4+ T cells from lung and draining lymph node of flu-infected mice
GEO Series GSE146626. Mus musculus. 7 samples. Type: Expression profiling by high throughput sequencing.
P14 T cells from C57BL6J draining lymph node after vaccinia-GP33
GEO Series GSE236283. Mus musculus. 1 samples. Type: Expression profiling by high throughput sequencing.
Specific pre-plasma cell states and local proliferation at the dark zone – medulla interface characterize germinal center-derived plasma cell differentiation in lymph node (Figure 4 and Figure 5)
GEO Series GSE275124. Mus musculus. 20 samples. Type: Expression profiling by high throughput sequencing.
Dataset related to article "Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment's intensification?"
<p>This record contains raw data related to article “Assessing the role of Stereotactic Body Radiation Therapy in a large cohort of patients with lymph node oligometastases: Does it affect systemic treatment's intensification?"</p> <p><strong>Background and purpose: </strong>Lymph nodes (LN) are common site of oligometastases and stereotactic body radiation therapy (SBRT) represents an effective ablative treatment. Aim of this study was to analyze a large cohort of nodal oligometastases treated with SBRT to identify impact on systemic therapy intensification, pattern of recurrence, and predictive factors.</p> <p><strong>Materials and methods: </strong>We included patients with a maximum of 5 oligometastases. Concomitant treatments were allowed. Patients were treated with Volumetric Modulated Arc Therapy (VMAT) and end points were local control of treated metastases (LC), locoregional nodal control (LRNC), distant nodal control (DNC), distant metastases free survival (DMFS), overall survival (OS) and freedom from treatment intensification (FFTI).</p> <p><strong>Results: </strong>418 LN were treated in 278 patients with 327 SBRT treatments. Patients were more commonly affected by colorectal (20.9%) and prostate cancer (17.99%). Most represented schedule was 45 Gy in 6 fractions, with a median BED10 of 78.75 Gy. After median follow-up of 15.1 months, LC at 1 and 2 years were 87.2% and 76.8%, respectively. Prostate primary tumor, small volume, oligorecurrence, and BED10 ≥75 Gy were associated with higher LC. One and 2 years FFTI were 82.8% and 74.5%; in patients reporting intensification of systemic therapy, median time was 8.43 months, while for patients who repeated SBRT, median FFTI was 14.6 months. Rates of LRNC at 1 and 2 years were 70.9% and 57.6%, and DNC were 82.0% and 77.9%.</p> <p><strong>Conclusion: </strong>With the present analysis, we confirmed on a large cohort the benefit from SBRT on lymph node oligometastases in multidisciplinary management. Combination of SBRT with new systemic therapies, including immunotherapy and targeted therapy, should be investigated to reduce the risk of progression out of the field of irradiation.</p>
Dataset related to article "Phase II trial of high dose stereotactic body radiation therapy for lymph node oligometastases"
<p>This record contains raw data related to article "Phase II trial of high dose stereotactic body radiation therapy for lymph node oligometastases"</p> <p>Lymph nodes are common sites of oligometastases for several primaries. Stereotactic body radiation therapy (SBRT) represents an effective treatment but no consensus exists regarding dose and fractionation. Aim of this trial was to evaluate safety and efficacy of high-dose SBRT. We included patients with 1 to 3 lymph node metastases. Primary end-point was safety, while secondary end-points were in-field local control (LC), out-field lymph nodal progression free survival (LPFS), distant metastasis free survival (DMFS), progression free survival (PFS) and overall survival (OS). 64 lesions in 52 patients were treated from 2015 to 2019. Most common primary tumor was genitourinary cancer (75%), in particular prostate cancer (65.4%). With a median follow-up of 24.4 months (range 3-49), treatment was very well tolerated, with only 4 (7.7%) patients reporting acute side effects, all classified as grade 1, in the form of pain, fatigue, nocturia and dysuria. No toxicity ≥ grade 2 were reported. Rates of LC at 1, 2 and 3 years were 97.9%, 82.1% and 82.1%. Male sex (HR 0.12, p value 0.014) was associated with improved LC. LPFS at 1, 2 and 3 years were 69.6%, 49.6% and 46.1%, respectively, and DMFS was 81.74%, 67.5% and 58.5%, respectively. Presence of lesions in other organs was correlated with inferior DMFS (HR 3.82, p = 0.042). PFS at 1, 2 and 3 years were 67.4%, 42.4% and 31.86%, respectively. OS at 1, 2 and 3 years were 97.3%, 94.2%, 84%, respectively and significantly correlated with in-field recurrence (HR 8.72, p = 0.000). Our prospective trial confirms safety and efficacy of SBRT in the management of lymph node metastases. Registered Clinical trial <a href="http://clinicaltrials.gov/show/NCT02570399">NCT02570399</a>.</p>
Properties after node removal and common graph drawn with common tRNAs
Open the record for dataset details and reuse information.
Compare graph properties when removing important nodes
Open the record for dataset details and reuse information.
Dataset related to article "External Validation and Comparison of Two Nomograms Predicting the Probability of Lymph Node Involvement in Patients subjected to Robot-Assisted Radical Prostatectomy and Concomitant Lymph Node Dissection: A Single Tertiary Center Experience in the MRI-Era "
<p>This record contains raw data related to article “External Validation and Comparison of Two Nomograms Predicting the Probability of Lymph Node Involvement in Patients subjected to Robot-Assisted Radical Prostatectomy and Concomitant Lymph Node Dissection: A Single Tertiary Center Experience in the MRI-Era"</p> <p>Abstract</p> <p><strong>Introduction: </strong> To externally validate and directly compare the performance of the Briganti 2012 and Briganti 2019 nomograms as predictors of lymph node invasion (LNI) in a cohort of patients treated with robot-assisted radical prostatectomy (RARP) and extended pelvic lymph node dissection (ePLND).</p> <p><strong>Materials and methods: </strong> After the exclusion of patients with incomplete biopsy, imaging, or clinical data, 752 patients who underwent RARP and ePLND between December 2014 to August 2021 at our center, were included. Among these patients, 327 (43.5%) had undergone multi-parametric MRI (mpMRI) and mpMRI-targeted biopsy. The preoperative risk of LNI was calculated for all patients using the Briganti 2012 nomogram, while the Briganti 2019 nomogram was used only in patients who had performed mpMRI with the combination of targeted and systematic biopsy. The performances of Briganti 2012 and 2019 models were evaluated using the area under the receiver-operating characteristics curve analysis, calibrations plot, and decision curve analysis.</p> <p><strong>Results: </strong> A median of 13 (IQR 9-18) nodes per patient was removed, and 78 (10.4%) patients had LNI at final pathology. The area under the curves (AUCs) for Briganti 2012 and 2019 were 0.84 and 0.82, respectively. The calibration plots showed a good correlation between the predicted probabilities and the observed proportion of LNI for both models, with a slight tendency to underestimation. The decision curve analysis (DCA) of the two models was similar, with a slightly higher net benefit for Briganti 2012 nomogram. In patients receiving both systematic- and targeted-biopsy, the Briganti 2012 accuracy was 0.85, and no significant difference was found between the AUCs of 2012 and 2019 nomograms (<em>p</em> = 0.296). In the sub-cohort of 518 (68.9%) intermediate-risk PCa patients, the Briganti 2012 nomogram outperforms the 2019 model in terms of accuracy (0.82 vs. 0.77), calibration curve, and net benefit at DCA.</p> <p><strong>Conclusion: </strong> The direct comparison of the two nomograms showed that the most updated nomogram, which included MRI and MRI-targeted biopsy data, was not significantly more accurate than the 2012 model in the prediction of LNI, suggesting a negligible role of mpMRI in the current population.</p>
Dataset related to article "Internal Guidelines for Reducing Lymph Node Contour Variability in Total Marrow and Lymph Node Irradiation "
<p>This record contains raw data related to article “Internal Guidelines for Reducing Lymph Node Contour Variability in Total Marrow and Lymph Node Irradiation"</p> <p><strong>Background: </strong> The total marrow and lymph node irradiation (TMLI) target includes the bones, spleen, and lymph node chains, with the latter being the most challenging structures to contour. We evaluated the impact of introducing internal contour guidelines to reduce the inter- and intraobserver lymph node delineation variability in TMLI treatments.</p> <p><strong>Methods: </strong> A total of 10 patients were randomly selected from our database of 104 TMLI patients so as to evaluate the guidelines' efficacy. The lymph node clinical target volume (CTV_LN) was recontoured according to the guidelines (CTV_LN_GL_RO1) and compared to the historical guidelines (CTV_LN_Old). Both topological (i.e., Dice similarity coefficient (DSC)) and dosimetric (i.e., V95 (the volume receiving 95% of the prescription dose) metrics were calculated for all paired contours.</p> <p><strong>Results: </strong> The mean DSCs were 0.82 ± 0.09, 0.97 ± 0.01, and 0.98 ± 0.02, respectively, for CTV_LN_Old vs. CTV_LN_GL_RO1, and between the inter- and intraobserver contours following the guidelines. Correspondingly, the mean CTV_LN-V95 dose differences were 4.8 ± 4.7%, 0.03 ± 0.5%, and 0.1 ± 0.1%.</p> <p><strong>Conclusions: </strong> The guidelines reduced the CTV_LN contour variability. The high target coverage agreement revealed that historical CTV-to-planning-target-volume margins were safe, even if a relatively low DSC was observed.</p>
Deep cervical lymph nodes of patients with multiple sclerosis show dysregulated B cells in the presence of Epstein-Barr virus2
<p>5´ scRNAseq data including TCR and BCR-seq data and CITE-seq data to reproduce the findings in the manuscript "Deep cervical lymph nodes of patients with multiple sclerosis show dysregulated B cells in the presence of Epstein-Barr virus". <br><br>The folder contains Seurat objects:</p><ul><li>msFNA_allData.rds (scRNAseq data)</li><li>msFNA_withBCR_Data.rds (BCR-seq data)</li><li>msFNA_withTCR_Data.rds (TCR-seq data)</li><li>msFNA_withCiteseq_Data.rds (CITE-seq data)</li></ul><p> </p>
Multimodal single-cell and spatial profiling reveals altered T cell-mediated immunity and B-cell follicular architecture in non-metastatic lymph nodes of patients with aggressive non-small cell lung c
GEO Series GSE316782. Homo sapiens. 18 samples. Type: Expression profiling by high throughput sequencing; Other.
Global Transcriptome Profiles in the Nodes of Rice During Spatial and Temporal Development
GEO Series GSE11896. Oryza sativa. 134 samples. Type: Expression profiling by array.
Effect of naringin in mouse lymph nodes
GEO Series GSE244047. Mus musculus. 6 samples. Type: Expression profiling by high throughput sequencing.
CITE-seq Analysis of Dendritic Cells in the Gut-Draining Lymph Node at Homeostasis with LIPSTIC Labeling of Akkermansia muciniphila-Presenting Cells
GEO Series GSE313298. Mus musculus. 2 samples. Type: Expression profiling by high throughput sequencing; Other.
The effect of natural feline coronavirus infection on the host immune response: a whole-transcriptome analysis on the mesenteric lymph nodes of cats with and without feline infectious peritonitis
GEO Series GSE152676. Felis catus. 24 samples. Type: Expression profiling by high throughput sequencing.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.